Q2 2026

Released Aug 6, 2026, after the close

10-Q filed Aug 10, 2026, 41 days after period end · 0001493152-26-036851

Q2 2026 · 10-Q

Revenue

$6.02M

+36.2% vs Q2 2025+15.4% vs Q1 2026

Net Income

$1.20M

+405.1% vs Q2 2025+755.0% vs Q1 2026

EPS Diluted

$0.11

+450.0% vs Q2 2025+1,000.0% vs Q1 2026

Gross Profit$4,026,000+44.0%

Operating Income$1,213,000+389.1%

Operating Cash Flowderived$681,000−31.5%

Margins · derived

Gross margin66.9%+3.7 pt vs Q2 2025

Operating margin20.2%+14.5 pt vs Q2 2025

Net margin19.9%+14.5 pt vs Q2 2025

What the release said

Metric	Q2 2026	Q2 2025	Q2 2024	Q2 2023
Revenue	$6.02M	$4.42M	$3.25M	$3.55M
Net Income	$1.20M	$237.00K	-$289.00K	-$433.00K
EPS Diluted	$0.11	$0.02	-$0.03	-$0.04

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR